title: Shelf-life of ɛ-lysyl-3-(trimethylstannyl)benzamide immunoconjugates, precursors for 211At labeling of antibodies.
abstract: Astatine-211 is possibly the most promising radionuclide for targeted α-particle therapy when it comes to the treatment of occult disseminated cancer. Preclinical research has proven effective, and patient studies have been initiated based on these results. However, a lack of production capacity and the complex radiochemistry of (211)At are major obstacles for research and prospective clinical applications. In the present study, astatination of immunoconjugates, already prepared well in advance before radiolabeling, was performed to investigate the possibility of formulating a kit-like reagent for the production of (211)At radiopharmaceuticals. The shelf-life of ɛ-lysyl-3-(trimethylstannyl)benzamide immunoconjugates was evaluated, that is, the effect of different storage times on the quality of the immunoconjugates. The quality being referred to is the capacity to maintain a good radiochemical yield and good cell-binding property after labeling with (211)At. The stability of the conjugates was found to be pH dependent with high stability at pH≥7 and less stability at pH≤5.5. The immunoconjugates (based on trastuzumab) could be kept for more than 3 months in a phosphate buffered saline solution (pH 7.4) at 4°C before labeling, without compromising the quality of the labeled product. The conjugates are also unaffected by storage at -20°C. Conjugates with a good shelf-life compatible with distant shipping as well as improved radiochemistry are important steps to facilitate further clinical progress with (211)At.
authors.affiliation: 1 Department of Radiation Physics, Sahlgrenska Academy at Göteborg University, Sahlgrenska University Hospital , Göteborg, Sweden .
authors.forename: Emma
authors.initials: E
authors.lastname: Aneheim
authors.forename: Jenny
authors.initials: J
authors.lastname: Halleröd
authors.forename: Per
authors.initials: P
authors.lastname: Albertsson
authors.forename: Holger
authors.initials: H
authors.lastname: Jensen
authors.forename: Stellan
authors.initials: S
authors.lastname: Holgersson
authors.forename: Sture
authors.initials: S
authors.lastname: Lindegren
mesh_terms: D000911:Antibodies, Monoclonal / Q000737:chemistry; D061067:Antibodies, Monoclonal, Humanized / Q000737:chemistry; D000970:Antineoplastic Agents / Q000737:chemistry; D001246:Astatine / Q000737:chemistry*; D001549:Benzamides / Q000737:chemistry*; D045744:Cell Line, Tumor; D004355:Drug Stability; D006801:Humans; D018796:Immunoconjugates / Q000737:chemistry*; D007553:Isotope Labeling; D019275:Radiopharmaceuticals / Q000737:chemistry; D000068878:Trastuzumab; D014298:Trimethyltin Compounds / Q000737:chemistry*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D001549:Benzamides; D018796:Immunoconjugates; D019275:Radiopharmaceuticals; D014298:Trimethyltin Compounds; D000068878:Trastuzumab; D001246:Astatine
keywords: antibodies; astatine-211; immunoconjugate; labeling; shelf-life